Cary, N.C.; Sept. 2, 2020 (Business Wire) –  CATO SMS unveiled its new brand today, revealing an updated look and logo capturing the company’s powerful offering following the merger of CATO Research, LLC and Specialized Medical Services-oncology BV (SMS-oncology). Now, as a fully integrated company, CATO SMS leverages 30 years of global experience to provide comprehensive regulatory support and full-service clinical trial solutions to small and emerging biopharmaceutical companies with a commitment to making trials digital.

CATO and SMS-oncology joined forces in 2019 to expand their global footprint, deepen their oncology and regulatory expertise, and broaden their suite of services. As one company, CATO SMS offers a unique blend of capabilities specializing in supporting biopharmaceutical companies with advancing drug development. CATO SMS has conducted 500+ trials in more than 25 countries, focusing on some of the most complex development areas including oncology, rare and orphan indications, and cell and gene therapy. The company has contributed to the successful development of over 50 marketed products and includes a prolific regulatory group that completes approximately 750 submissions of various types annually.

“Our new brand reflects the value and insight CATO SMS brings to our clients as one organization,” said Mark A. Goldberg, M.D., executive chairman, CATO SMS. “We’ve formed a high-performance team across a variety of therapeutic areas, from our global regulatory experts to our center of excellence in oncology. We are excited to provide our clients with a broader set of solutions supported by the same high level of operational excellence and personalized customer service they have come to expect from us over the past three decades.”

CATO SMS’ new website is now live at CATO-SMS.com.

About CATO SMS
CATO SMS is a provider of specialized clinical research solutions. The company was formed when CATO Research, LLC and Specialized Medical Services-oncology BV (SMS-oncology) merged in 2019. With more than 30 years of experience focusing on the needs of small and emerging biopharmaceutical companies, CATO SMS effectively designs and executes studies ⁠— from strategy to approval ⁠— in complex indications and modalities across a variety of therapeutic areas, with a proven center of excellence in oncology. CATO SMS’ regulatory, therapeutic, and operational expertise supports clients with achieving their goals and exceeding their expectations. Visit CATO-SMS.com for more information.

Back to Press Releases